Drug intelligence / Profile preview

Lactobacillus acidophilus FB0012

Development stage
Unknown
Modality
Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration
Oral
01

Overview

Lactobacillus acidophilus FB0012 is a specific strain of *Lactobacillus acidophilus*, a gram-positive, non-sporulating, rod-shaped bacterium commonly found as part of the natural flora of the human gut and vagina. As a probiotic, *Lactobacillus acidophilus* is widely recognized for its beneficial effects on human health, primarily by modulating the intestinal microbiota and immune system. Its mechanism of action involves producing lactic acid, which lowers the intestinal pH and inhibits the growth of pathogenic bacteria. It also produces other antimicrobial substances like bacteriocins and hydrogen peroxide, and competes with pathogens for adhesion sites and nutrients in the gut. Furthermore, *Lactobacillus acidophilus* can enhance gut barrier function, modulate host immune responses, and improve conditions such as lactose intolerance. While *Lactobacillus acidophilus* in general is used in dietary supplements and investigated for various health benefits, specific information regarding the developer, manufacturer, and primary indication for the FB0012 strain is not publicly available.

Beyond the preview

Go deeper on Lactobacillus acidophilus FB0012.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lactobacillus acidophilus FB0012.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call